Advanced search
Publication Cover
Expert Review of Vaccines Volume 11, 2012 - Issue 9
Submit an article Journal homepage
1,105
Views
177
CrossRef citations to date
0
Altmetric
Review

Chikungunya virus and prospects for a vaccine

Scott C Weaver Institute for Human Infections and Immunity, Sealy Center for Vaccine Development and Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Institute for Human Infections and Immunity, Sealy Center for Vaccine Development and Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA. [email protected]
,
Jorge E Osorio Inviragen, Inc., Madison, Wisconsin and Fort Collins, Colorado, WI, USA; Inviragen, Inc., Madison, Wisconsin and Fort Collins, Colorado, WI, USA
,
Jill A Livengood Inviragen, Inc., Madison, Wisconsin and Fort Collins, Colorado, WI, USA; Inviragen, Inc., Madison, Wisconsin and Fort Collins, Colorado, WI, USA
,
Rubing Chen Institute for Human Infections and Immunity, Sealy Center for Vaccine Development and Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA; Institute for Human Infections and Immunity, Sealy Center for Vaccine Development and Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA
&
Dan T Stinchcomb Inviragen, Inc., Madison, Wisconsin and Fort Collins, Colorado, WI, USA; Inviragen, Inc., Madison, Wisconsin and Fort Collins, Colorado, WI, USA
Pages 1087-1101 | Published online: 09 Jan 2014

References

  • Ross RW. The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic. J. Hyg. (Lond.) 54(2), 177–191 (1956).
  • Weaver SC, Frey TK, Huang HV et al. Togaviridae. In: Virus Taxonomy, VIIIth Report of the ICTV. Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA (Eds). Elsevier/Academic Press, London, UK, 999–1008 (2005).
  • Brighton SW, Simson IW. A destructive arthropathy following chikungunya virus arthritis – a possible association. Clin. Rheumatol. 3(2), 253–258 (1984).
  • Gérardin P, Fianu A, Malvy D et al. Perceived morbidity and community burden after a chikungunya outbreak: the TELECHIK survey, a population-based cohort study. BMC Med. 9, 5 (2011).
  • Vijayakumar KP, Nair Anish TS, George B, Lawrence T, Muthukkutty SC, Ramachandran R. Clinical profile of chikungunya patients during the epidemic of 2007 in Kerala, India. J. Glob. Infect. Dis. 3(3), 221–226 (2011).
  • de Andrade DC, Jean S, Clavelou P, Dallel R, Bouhassira D. Chronic pain associated with the chikungunya fever: long-lasting burden of an acute illness. BMC Infect. Dis. 10, 31 (2010).
  • Chow A, Her Z, Ong EK et al. Persistent arthralgia induced by chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. J. Infect. Dis. 203(2), 149–157 (2011).
  • Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P et al. Persistent chronic inflammation and infection by chikungunya arthritogenic alphavirus in spite of a robust host immune response. J. Immunol. 184(10), 5914–5927 (2010).
  • Krishnamoorthy K, Harichandrakumar KT, Krishna Kumari A, Das LK. Burden of chikungunya in India: estimates of disability adjusted life years (DALY) lost in 2006 epidemic. J. Vector Borne Dis. 46(1), 26–35 (2009).
  • Kuhn RJ. Togaviridae: The viruses and their replication. In: Fields’ Virology (5th Edition). Knipe DM, Howley PM (Eds). Lippincott, Williams and Wilkins, NY, USA, 1001–1022 (2007).
  • Diallo M, Thonnon J, Traore-Lamizana M, Fontenille D. Vectors of chikungunya virus in Senegal: current data and transmission cycles. Am. J. Trop. Med. Hyg. 60(2), 281–286 (1999).
  • Jupp PG, McIntosh BM, Dos Santos I, DeMoor P. Laboratory vector studies on six mosquito and one tick species with chikungunya virus. Trans. R. Soc. Trop. Med. Hyg. 75(1), 15–19 (1981).
  • Jupp PG, McIntosh BM. Aedes furcifer and other mosquitoes as vectors of chikungunya virus at Mica, northeastern Transvaal, South Africa. J. Am. Mosq. Control Assoc. 6(3), 415–420 (1990).
  • Paterson HE, Mcintosh BM. Further studies on the chikungunya outbreak in southern rhodesia in 1962. ii. transmission experiments with the Aedes furcifer-taylori group of mosquitoes and with a member of the anopheles gambiae complex. Ann. Trop. Med. Parasitol. 58, 52–55 (1964).
  • Mcintosh BM, Paterson HE, Mcgillivray G, Desousa J. Further studies on the chikungunya outbreak in southern rhodesia in 1962. i. mosquitoes, wild primates and birds in relation to the epidemic. Ann. Trop. Med. Parasitol. 58, 45–51 (1964).
  • McIntosh BM, Paterson HE, Donaldson JM, De Sousa J. Chikungunya virus: viral susceptibility and transmission studies with some vertebrates and mosquitoes. S. African J. Med. Sci. 28, 45–50 (1963).
  • Paul SD, Singh KR. Experimental infection of Macaca radiata with chikungunya virus and transmission of virus by mosquitoes. Indian J. Med. Res. 56(6), 802–811 (1968).
  • Carey DE. Chikungunya and dengue: a case of mistaken identity? J. Hist. Med. Allied Sci. 26(3), 243–262 (1971).
  • Wolfe ND, Kilbourn AM, Karesh WB et al. Sylvatic transmission of arboviruses among Bornean orangutans. Am. J. Trop. Med. Hyg. 64(5-6), 310–316 (2001).
  • Apandi Y, Nazni WA, Noor Azleen ZA et al . The first isolation of chikungunya virus from nonhuman primates in Malaysia. J. Gen. Mol. Virol. 1, 35–39 (2009).
  • Peyrefitte CN, Bessaud M, Pastorino BA et al. Circulation of chikungunya virus in Gabon, 2006-2007. J. Med. Virol. 80(3), 430–433 (2008).
  • Peyrefitte CN, Rousset D, Pastorino BA et al. Chikungunya virus, Cameroon, 2006. Emerging Infect. Dis. 13(5), 768–771 (2007).
  • Weaver SC. Evolutionary influences in arboviral disease. Curr. Top. Microbiol. Immunol. 299, 285–314 (2006).
  • Weaver SC, Reisen WK. Present and future arboviral threats. Antiviral Res. 85(2), 328–345 (2010).
  • Ooi EE, Gubler D. Dengue virus – mosquito interactions. In: Frontiers in Dengue Virus Research. Hanley KA, Weaver SC (Eds). Horizon Press, Norwich, UK (2010).
  • Panning M, Grywna K, van Esbroeck M, Emmerich P, Drosten C. Chikungunya fever in travelers returning to Europe from the Indian Ocean region, 2006. Emerging Infect. Dis. 14(3), 416–422 (2008).
  • Leo YS, Chow AL, Tan LK, Lye DC, Lin L, Ng LC. Chikungunya outbreak, Singapore, 2008. Emerging Infect. Dis. 15(5), 836–837 (2009).
  • Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog. 3(12), e201 (2007).
  • Tsetsarkin KA, McGee CE, Volk SM, Vanlandingham DL, Weaver SC, Higgs S. Epistatic roles of E2 glycoprotein mutations in adaption of chikungunya virus to Aedes albopictus and Ae. aegypti mosquitoes. PLoS ONE 4(8), e6835 (2009).
  • Tsetsarkin KA, Weaver SC. Sequential adaptive mutations enhance efficient vector switching by Chikungunya virus and its epidemic emergence. PLoS Pathog. 7(12), e1002412 (2011).
  • Vazeille M, Moutailler S, Coudrier D et al. Two Chikungunya isolates from the outbreak of La Reunion (Indian Ocean) exhibit different patterns of infection in the mosquito, Aedes albopictus. PLoS ONE 2(11), e1168 (2007).
  • Tsetsarkin KA, Chen R, Sherman MB, Weaver SC. Chikungunya virus: evolution and genetic determinants of emergence. Curr. Opin. Virol. 1(4), 310–317 (2011).
  • Powers AM, Brault AC, Tesh RB, Weaver SC. Re-emergence of Chikungunya and O’nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. J. Gen. Virol. 81(Pt 2), 471–479 (2000).
  • Volk SM, Chen R, Tsetsarkin KA et al. Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates. J. Virol. 84(13), 6497–6504 (2010).
  • Bryant JE, Holmes EC, Barrett AD. Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas. PLoS Pathog. 3(5), e75 (2007).
  • Ng LC, Hapuarachchi HC. Tracing the path of chikungunya virus–evolution and adaptation. Infect. Genet. Evol. 10(7), 876–885 (2010).
  • Chretien JP, Anyamba A, Bedno SA et al. Drought-associated chikungunya emergence along coastal East Africa. Am. J. Trop. Med. Hyg. 76(3), 405–407 (2007).
  • Powers AM, Logue CH. Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J. Gen. Virol. 88(Pt 9), 2363–2377 (2007).
  • Sang RC, Ahmed O, Faye O et al. Entomologic investigations of a chikungunya virus epidemic in the Union of the Comoros, 2005. Am. J. Trop. Med. Hyg. 78(1), 77–82 (2008).
  • Arankalle VA, Shrivastava S, Cherian S et al. Genetic divergence of chikungunya viruses in India (1963-2006) with special reference to the 2005–2006 explosive epidemic. J. Gen. Virol. 88(Pt 7), 1967–1976 (2007).
  • Lanciotti RS, Kosoy OL, Laven JJ et al. Chikungunya virus in US travelers returning from India, 2006. Emerg. Infect. Dis. 13(5), 764–767 (2007).
  • Ng LC, Tan LK, Tan CH et al. Entomologic and virologic investigation of chikungunya, Singapore. Emerg. Infect. Dis. 15(8), 1243–1249 (2009).
  • Rezza G, Nicoletti L, Angelini R et al . CHIKV study group. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet 370(9602), 1840–1846 (2007).
  • Grandadam M, Caro V, Plumet S et al. Chikungunya virus, southeastern France. Emerging Infect. Dis. 17(5), 910–913 (2011).
  • Schuffenecker I, Iteman I, Michault A et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med. 3(7), e263 (2006).
  • Vashishtha M, Phalen T, Marquardt MT, Ryu JS, Ng AC, Kielian M. A single point mutation controls the cholesterol dependence of Semliki Forest virus entry and exit. J. Cell Biol. 140(1), 91–99 (1998).
  • Pagès F, Peyrefitte CN, Mve MT et al. Aedes albopictus mosquito: the main vector of the 2007 chikungunya outbreak in Gabon. PLoS ONE 4(3), e4691 (2009).
  • de Lamballerie X, Leroy E, Charrel RN, Ttsetsarkin K, Higgs S, Gould EA. Chikungunya virus adapts to tiger mosquito via evolutionary convergence: a sign of things to come? Virol. J. 5, 33 (2008).
  • Niyas KP, Abraham R, Unnikrishnan RN et al. Molecular characterization of chikungunya virus isolates from clinical samples and adult Aedes albopictus mosquitoes emerged from larvae from Kerala, South India. Virol. J. 7, 189 (2010).
  • Lambrechts L, Scott TW, Gubler DJ. Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission. PLoS Negl. Trop. Dis. 4(5), e646 (2010).
  • Honório NA, Castro MG, Barros FS, Magalhães Mde A, Sabroza PC. The spatial distribution of Aedes aegypti and Aedes albopictus in a transition zone, Rio de Janeiro, Brazil. Cad. Saude. Publica. 25(6), 1203–1214 (2009).
  • Rey JR, Nishimura N, Wagner B, Braks MA, O’Connell SM, Lounibos LP. Habitat segregation of mosquito arbovirus vectors in South Florida. J. Med. Entomol. 43(6), 1134–1141 (2006).
  • Braks MA, Honório NA, Lourençqo-De-Oliveira R, Juliano SA, Lounibos LP. Convergent habitat segregation of Aedes aegypti and Aedes albopictus (Diptera: Culicidae) in southeastern Brazil and Florida. J. Med. Entomol. 40(6), 785–794 (2003).
  • Tewari SC, Thenmozhi V, Katholi CR, Manavalan R, Munirathinam A, Gajanana A. Dengue vector prevalence and virus infection in a rural area in South India. Trop. Med. Int. Health 9(4), 499–507 (2004).
  • Tandon N, Ray S. Breeding habitats and larval indices of Aedes aegypti and Ae. albopictus in the residential areas of Calcutta City. J. Commun. Dis. 32(3), 180–184 (2000).
  • Tsetsarkin KA, Chen R, Leal G et al. Chikungunya virus emergence is constrained in Asia by lineage-specific adaptive landscapes. Proc. Natl Acad. Sci. USA. 108(19), 7872–7877 (2011).
  • Lemant J, Boisson V, Winer A et al. Serious acute chikungunya virus infection requiring intensive care during the Reunion Island outbreak in 2005-2006. Crit. Care Med. 36(9), 2536–2541 (2008).
  • Das T, Jaffar-Bandjee MC, Hoarau JJ et al. Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus. Prog. Neurobiol. 91(2), 121–129 (2010).
  • Economopoulou A, Dominguez M, Helynck B et al. Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005-2006 outbreak on Réunion. Epidemiol. Infect. 137(4), 534–541 (2009).
  • Borgherini G, Poubeau P, Staikowsky F et al. Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients. Clin. Infect. Dis. 44(11), 1401–1407 (2007).
  • Brighton SW, Prozesky OW, de la Harpe AL. Chikungunya virus infection. A retrospective study of 107 cases. S. Afr. Med. J. 63(9), 313–315 (1983).
  • Manimunda SP, Vijayachari P, Uppoor R et al. Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging. Trans. R. Soc. Trop. Med. Hyg. 104(6), 392–399 (2010).
  • Ganu MA, Ganu AS. Post-chikungunya chronic arthritis–our experience with DMARDs over two year follow-up. J. Assoc. Physicians India 59, 83–86 (2011).
  • Kam YW, Lum FM, Teo TH et al. Early neutralizing IgG response to chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol. Med. 4(4), 330–343 (2012).
  • Kam YW, Simarmata D, Chow A et al. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J. Infect. Dis. 205(7), 1147–1154 (2012).
  • Sourisseau M, Schilte C, Casartelli N et al. Characterization of re-emerging chikungunya virus. PLoS Pathog. 3(6), e89 (2007).
  • Arpino C, Curatolo P, Rezza G. Chikungunya and the nervous system: what we do and do not know. Rev. Med. Virol. 19(3), 121–129 (2009).
  • Wauquier N, Becquart P, Nkoghe D, Padilla C, Ndjoyi-Mbiguino A, Leroy EM. The acute phase of chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation. J. Infect. Dis. 204(1), 115–123 (2011).
  • Aoyama I, Uno K, Yumisashi T et al. A case of chikungunya fever imported from India to Japan, follow-up of specific IgM and IgG antibodies over a 6-month period. Jpn. J. Infect. Dis. 63(1), 65–66 (2010).
  • Couderc T, Chrétien F, Schilte C et al. A mouse model for chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog. 4(2), e29 (2008).
  • Ziegler SA, Lu L, da Rosa AP, Xiao SY, Tesh RB. An animal model for studying the pathogenesis of chikungunya virus infection. Am. J. Trop. Med. Hyg. 79(1), 133–139 (2008).
  • Ziegler SA, Nuckols J, McGee CE et al. In vivo imaging of chikungunya virus in mice and Aedes mosquitoes using a Renilla luciferase clone. Vector Borne Zoonotic Dis. 11(11), 1471–1477 (2011).
  • Morrison TE, Oko L, Montgomery SA et al. A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am. J. Pathol. 178(1), 32–40 (2011).
  • Gardner J, Anraku I, Le TT et al. Chikungunya virus arthritis in adult wild-type mice. J. Virol. 84(16), 8021–8032 (2010).
  • Partidos CD, Weger J, Brewoo J et al. Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling. Vaccine 29(16), 3067–3073 (2011).
  • Gardner CL, Burke CW, Higgs ST, Klimstra WB, Ryman KD. Interferon-α/β deficiency greatly exacerbates arthritogenic disease in mice infected with wild-type chikungunya virus but not with the cell culture-adapted live-attenuated 181/25 vaccine candidate. Virology 425(2), 103–112 (2012).
  • Holzer GW, Coulibaly S, Aichinger G et al. Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection. Vaccine 29(24), 4132–4141 (2011).
  • Shah KV, Gibbs CJ Jr, Banerjee G. Virological investigation of the epidemic of haemorrhagic fever in Calcutta: isolation of three strains of chikungunya virus. Indian J. Med. Res. 52, 676–683 (1964).
  • Reed DS, Lind CM, Lackemeyer MG, Sullivan LJ, Pratt WD, Parker MD. Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus. Vaccine 23(24), 3139–3147 (2005).
  • Verrier B, Le Grand R, Ataman-Onal Y et al. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08. DNA Cell Biol. 21(9), 653–658 (2002).
  • Vierboom MP, Jonker M, Tak PP, ‘t Hart BA. Preclinical models of arthritic disease in nonhuman primates. Drug Discov. Today 12(7-8), 327–335 (2007).
  • Walsh GP, Tan EV, dela Cruz EC et al. The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat. Med. 2(4), 430–436 (1996).
  • Labadie K, Larcher T, Joubert C et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J. Clin. Invest. 120(3), 894–906 (2010).
  • Inoue S, Morita K, Matias RR et al. Distribution of three arbovirus antibodies among monkeys (Macaca fascicularis) in the Philippines. J. Med. Primatol. 32(2), 89–94 (2003).
  • Kaschula VR, Van Dellen AF, de Vos V. Some infectious diseases of wild vervet monkeys (Cercopithecus aethiops pygerythrus) in South Africa. J. S. Afr. Vet. Assoc. 49(3), 223–227 (1978).
  • Eckels KH, Harrison VR, Hetrick FM. Chikungunya virus vaccine prepared by Tween-ether extraction. Appl. Microbiol. 19(2), 321–325 (1970).
  • Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA. Phase 2 safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am. J. Trop. Med. Hyg. 62(6), 681–685 (2000).
  • Harrison VR, Eckels KH, Bartelloni PJ, Hampton C. Production and evaluation of a formalin-killed chikungunya vaccine. J. Immunol. 107(3), 643–647 (1971).
  • Tiwari M, Parida M, Santhosh SR, Khan M, Dash PK, Rao PV. Assessment of immunogenic potential of Vero adapted formalin-inactivated vaccine derived from novel ECSA genotype of chikungunya virus. Vaccine 27(18), 2513–2522 (2009).
  • Wang E, Volkova E, Adams AP et al. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine 26(39), 5030–5039 (2008).
  • Wang E, Kim DY, Weaver SC, Frolov I. Chimeric Chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response. J. Virol. 85(17), 9249–9252 (2011).
  • Akahata W, Yang ZY, Andersen H et al. A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection. Nat. Med. 16(3), 334–338 (2010).
  • Muthumani K, Lankaraman KM, Laddy DJ et al. Immunogenicity of novel consensus-based DNA vaccines against chikungunya virus. Vaccine 26(40), 5128–5134 (2008).
  • Metz SW, Geertsema C, Martina BE et al. Functional processing and secretion of chikungunya virus E1 and E2 glycoproteins in insect cells. Virol. J. 8, 353 (2011).
  • Wang D, Suhrbier A, Penn-Nicholson A et al. A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine 29(15), 2803–2809 (2011).
  • White A, Berman S, Lowenthal JP. Comparative immunogenicities of chikungunya vaccines propagated in monkey kidney monolayers and chick embryo suspension cultures. Appl. Microbiol. 23(5), 951–952 (1972).
  • Levitt NH, Ramsburg HH, Hasty SE, Repik PM, Cole FE Jr, Lupton HW. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine 4(3), 157–162 (1986).
  • McClain DJ, Pittman PR, Ramsburg HH et al. Immunologic interference from sequential administration of live-attenuated alphavirus vaccines. J. Infect. Dis. 177(3), 634–641 (1998).
  • Gorchakov R, Wang E, Leal G et al. Attenuation of chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein. J. Virol. 86(11), 6084–6096 (2012).
  • Mallilankaraman K, Shedlock DJ, Bao H et al. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl. Trop. Dis. 5(1), e928 (2011).
  • Plante K, Wang E, Partidos CD et al. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog. 7(7), e1002142 (2011).
  • Darwin JR, Kenney JL, Weaver SC. Transmission potential of two chimeric chikungunya vaccine candidates in the urban mosquito vectors, Aedes aegypti and Ae. albopictus. Am. J. Trop. Med. Hyg. 84(6), 1012–1015 (2011).
  • Sumathy K, Ella KM. Genetic diversity of chikungunya virus, India 2006-2010: evolutionary dynamics and serotype analyses. J. Med. Virol. 84(3), 462–470 (2012).
  • Fiore AE, Finestone SM, Bell BP. Hepatitis A vaccine. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Elsevier-Saunders, PA, USA 177–203 (2008).
  • Siber GR, Chang I, Baker S et al. Estimating the protective concentration of antipneumococcal capsular polysaccharide antibodies. Vaccine 25(19), 3816–3826 (2007).
  • Jódar L, Butler J, Carlone G et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21(23), 3265–3272 (2003).
  • Chen RT, Markowitz LE, Albrecht P et al. Measles antibody: reevaluation of protective titers. J. Infect. Dis. 162(5), 1036–1042 (1990).
  • Dowdle WR, Coleman MT, Mostow SR, Kaye HS, Schoenbaum SC. Inactivated influenza vaccines. 2. Laboratory indices of protection. Postgrad. Med. J. 49(569), 159–163 (1973).
  • Mason RA, Tauraso NM, Spertzel RO, Ginn RK. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl. Microbiol. 25(4), 539–544 (1973).
  • Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine 23(45), 5205–5211 (2005).
  • Kreil TR, Burger I, Bachmann M, Fraiss S, Eibl MM. Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages. Clin. Exp. Immunol. 110(3), 358–361 (1997).
  • Kreil TR, Eibl MM. Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. J. Virol. 71(4), 2921–2927 (1997).
  • WHO, UNICEF, World Bank. State of the World’s Vaccines and Immunization (3rd Edition). WHO Press, Geneva, Switzerland (2009).
  • Ehreth J. The value of vaccination: a global perspective. Vaccine 21(27–30), 4105–4117 (2003).
  • Tu HA, Woerdenbag HJ, Kane S, Riewpaiboon A, van Hulst M, Postma MJ. Economic evaluations of hepatitis B vaccination for developing countries. Expert Rev. Vaccines 8(7), 907–920 (2009).
  • Zhang R, Hryc CF, Cong Y et al. 4.4 Å cryo-EM structure of an enveloped alphavirus Venezuelan equine encephalitis virus. EMBO J. 30(18), 3854–3863 (2011).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.